Collectively, the BV-based IL-15:IL-15Rα cell-based cancer vaccine induced potent antitumor responses in both the spleen and the circulatory system through a tumor antigen-specific CD8+ T cell-dependent mechanism. This evidence concerns the gene CD8A and neoplasm.